ESSA Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

South san francisco, calif. and vancouver, bc, april 9, 2024 /prnewswire/ - essa pharma inc. ("essa", or the "company") (nasdaq: epix), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the company will be presenting at the 2024 bloom burton & co. healthcare investor conference on tuesday, april 16, 2024 at 2:30 p.m.

South san francisco, usa and vancouver, canada , march 7, 2024  /prnewswire/ - essa pharma inc. ("essa" or the "company") (nasdaq: epix), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its annual general meeting of shareholders held virtually on march 6, 2024 (the "meeting"). at the meeting, the shareholders of the company (the "shareholders") resolved to set the number of directors of the company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, david r.

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in psa in phase 1 dose escalation in patients with mcrpc, including 81% of patients achieving psa90, 69% of patients achieving psa90 in less than 90 days, and 63% of patients achieving psa

South san francisco, california and vancouver, canada , feb. 6, 2024 /prnewswire/ - essa pharma inc. ("essa", or the "company") (nasdaq: epix), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the company will be participating in a virtual fireside chat at the oppenheimer 34th annual healthcare life sciences conference on tuesday, february 13, 2024, at 12:40 p.m. et. david.

Phase 1 dose escalation complete for masofaniten (epi-7386)/enzalutamide combination study in patients with mcrpc; compelling safety and efficacy data reported at prostate cancer foundation 2023 scientific retreat and esmo 2023 head-to-head phase 2 dose expansion underway evaluating masofaniten (epi-7386)/enzalutamide combination versus enzalutamide monotherapy in patients with mcrpc south san francisco, california and vancouver, canada , dec. 12, 2023 /prnewswire/ - essa pharma inc. ("essa", or the "company") (nasdaq: epix), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended september 30, 2023...

EPIX is targeting prostate cancer with its lead and only asset EPI-7386. While there's some rationale to the molecule's science, there's not a lot of convincing data yet.

The stock has pulled back from the 2x pop after the recent data of EPI-7386+Xtandi in post-chemotherapy metastatic castration-resistant prostate cancer, mCRPC. The efficacy of the EPI-7386+Xtandi combination in mCRPC beats that of currently approved drugs by a significant margin.

Check these strategies out for buying penny stocks right no The post 3 Beginner Penny Stocks Trading Mistakes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Use these strategies for making money with penny stocks The post Top Strategies for Making Money With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

ESSA Pharma (NASDAQ: EPIX ) stock is flying higher on Wednesday following the release of data from a Phase 1/2 study of EPI-7386. EPI-7386 is a drug in development for the treatment of metastatic castration-resistant prostate cancer.

Shares of early-stage prostate cancer concern ESSA Pharma Inc. are down 90% since May 2021 as trial data delays and vague messaging suggest that its therapy is running into issues about effectiveness and the market size for its therapy. It does not help that management has not conducted a conference call to better explain the clinical trial situation.

Insiders love these 3 penny stocks in July 2022 The post 3 Best Penny Stocks To Buy According To Insiders; 1 Bet Over $1.7 Million appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

ESSA Pharma developed a novel mode of action drug, EPI-7386, for the treatment of metastatic castrate-resistant prostate cancer. Pre-clinical and early Ph 1 results are promising. ESSA's share price crashed in mid-Aug when a change in the Ph 1 trial protocol was announced, and a delay in the expected Ph 1 monotherapy trial data release. I believe the market overreacted.

IRVING, Texas, and HOUSTON, and VANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ --  Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, and ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today a Precision Development program to support ESSA's ongoing clinical development of EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer ("mCRPC") failing current standard-of-care therapies. Under the terms of the agreement, Caris and ESSA will evaluate patient blood samples to assess genetic profiles utilizing Caris' Whole Transcriptome Sequencing (WTS) and Whole Exome Sequencing (WES) platform.

VANCOUVER, Canada and HOUSTON, Texas, Aug. 31, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting one-on-one meetings with investors at two upcoming virtual investor conferences.